ClinicalTrials.gg
Not yet recruitingNCT07734077MPN-RC 129Updated Jul 29, 2026

Revumenib in Patients With Myelofibrosis

A Phase 1/2 interventional study of Revumenib and Ruxolitinib in Myelofibrosis, Post-polycythemia Vera Myelofibrosis and Post-essential Thrombocythemia Myelofibrosis, sponsored by John Mascarenhas. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by John Mascarenhas · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Primary Myelofibrosis by John Mascarenhas — 3 open to participants now, 4 under way, none of them phase 3. Primary Myelofibrosis · John Mascarenhas.

Planned enrollment
2nd of 11
32 · median 20
Started
2026
with 1 other
Phase 1/2
2 of 11
1 open now
Registered
10th of 11
by date

Among the 11 studies in Primary Myelofibrosis by John Mascarenhas, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2026, is one of 2 in phase 1/2, and was the 10th registered.

Primary Myelofibrosis

628 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

3 of the 11 studies in Primary Myelofibrosis by John Mascarenhas are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Primary Myelofibrosis by John Mascarenhas, or all of them as a file.
02

Study summary

This is a Phase Ib/II 2 study investigating the safety and efficacy of revumenib in two cohorts of participants with myelofibrosis. COHORT-1 will investigate the safety of revumenib as monotherapy in participants with myelofibrosis previously treated with a JAK inhibitor. Following confirmation of safety in COHORT-1, the study will proceed with enrollment in COHORT-2, which will evaluate the efficacy and safety of revumenib in combination with a JAK inhibitor.

Read the detailed description

This is a Phase Ib/II 2 study investigating the safety and efficacy of revumenib in two cohorts of participants with myelofibrosis. COHORT-1 will investigate the safety of revumenib as monotherapy in participants with myelofibrosis previously treated with a JAK inhibitor. Following confirmation of safety in COHORT-1, the study will proceed with enrollment in COHORT-2, which will evaluate the efficacy and safety of revumenib in combination with a JAK inhibitor. COHORT-2 will enroll participants on stable dose of a JAK inhibitor (ruxolitinib, fedratinib, or momelotinib) for at least 12 weeks at time of enrollment and who demonstrate suboptimal response as evidenced by persistent splenomegaly, symptoms or transfusion-dependent anemia, with revumenib added to existing JAK inhibitor therapy. The researchers hypothesize that revumenib will demonstrate a favorable safety profile in myelofibrosis participants, and demonstrate clinical activity (response of CR, PR or CI by IWG-MRT and ELN criteria) in participants with suboptimal response to a JAK inhibitor.

03

Conditions studied

  • Myelofibrosis
  • Post-polycythemia Vera Myelofibrosis
  • Post-essential Thrombocythemia Myelofibrosis

Browse trials for

Keywords

  • Myelofibrosis
  • Revumenib
  • JAK inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Adults ≥ 18 years of age at time of signing the
  • Participants must voluntarily sign informed consent form (ICF) and be willing and able to adhere to the study visit schedule and all protocol requirements.
  • Have an (ECOG) performance status ≤ 2
  • Participants must have a confirmed diagnosis of PMF, post-ET-MF or post-PV-MF as per the WHO diagnostic criteria, with intermediate-1 or higher risk disease by DIPSS (14.1).
  • Criteria for COHORT-1 (Monotherapy): Treated with at least one prior line of JAK inhibitor therapy to which they were /resistant, lost response, or intolerant, or is not a candidate for approved JAK inhibitor therapy per investigator judgement, and with one or more of the following features of active disease:

    • Spleen palpable ≥ 5 cm below the left costal margin or > 450cm3 by MRI/CT
    • MPN-SAF TSS ≥ 10
    • Transfusion dependence (requiring at least 6 units of PRBCs in the 12 weeks prior to study enrollment, for a \< 8.5g/dL in the absence of bleeding or treatment-induced anemia)
  • Criteria for COHORT-2 (Combination therapy): Currently receiving treatment with an approved JAK inhibitor (including ruxolitinib, fedratinib, or momelotinib) with stable dose for at least 12 weeks prior to study enrollment, and with one or more of the following features of active disease:
  • Spleen palpable ≥ 5 cm below the left costal margin or > 450cm3 by MRI/CT
  • MPN-SAF TSS ≥ 10
  • Transfusion dependence (requiring at least 6 units of PRBCs in the 12 weeks prior to study enrollment, for a hemoglobin \< 8.5g/dL in the absence of bleeding or treatment-induced anemia)
  • Adequate organ function as demonstrated by the following within 28 days prior to Cycle 1 Day 1:

    • (SGPT) and/or AST (SGOT) \< 3 × the (ULN), or \< 5 × ULN if, upon judgment of the treating physician, it is believed to be due to MF-related extramedullary hematopoiesis (EMH);
    • Total \< 3 × ULN for age (\< 4 x ULN for age if attributed to MF related EMH or Gilbert's syndrome)
    • ≥ 30 mL/min by Cockcroft Gault formula;
    • (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 × upper limit of normal (ULN)
    • Adequate cardiac function defined as of ≥50% by echocardiogram or multigated acquisition (MUGA) scan
    • Bone marrow and/or peripheral blood blast count \< 10%;
    • (ANC) ≥ 1000 mm3; and
    • count ≥ 75 x 109/L at time of enrollment
  • ≤ 450msec at screening
  • Recovery to ≤ Grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia
  • of at least six months
  • Females of must have a negative serum pregnancy test at Screening and a negative urine or serum pregnancy test within 72 hours before the initiation of protocol therapy. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be obtained. Participants are considered to be not of childbearing potential if they are considered to be or surgically sterilized (eg, , hysterectomy, bilateral salpingectomy). Females who have been amenorrheic for at least 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anti-estrogens, ovarian suppression or any other reversible reason.

    • Females of childbearing potential must be willing to use a highly effective method of from the time of first study intervention dose through the required contraceptive period (4 months following the last dose of study drug) and must be willing to refrain from in vitro fertilization and egg donation during the required contraceptive period.
    • Males must be surgically sterile or agree to use barrier contraception (male condoms) from the time of first study intervention dose through the required contraceptive period of 4 months after last dose of study drug. Males must be willing to refrain from sperm donation during the required contraceptive period.
  • Able to adhere to the study visit schedule and all protocol requirements Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Treatment with any MF-directed therapy (including therapies) within 2 weeks or 5 half-lives, whichever is shorter, of Cycle 1 Day 1

    • Participants in COHORT-1 should not have received a JAK inhibitor within 14 days prior to Cycle 1 Day 1. Participants who remain on JAK inhibitor at time of screening should be tapered off per investigator discretion.
    • Hydroxyurea is permitted until the day prior to C1D1, if needed for disease control.
  • Undergone hematopoietic stem cell transplant (allo-HSCT) within the last 6 months prior to enrollment, or with active and/or on therapy.
  • Not currently a candidate for allo-HSCT, per investigator discretion. Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible.
  • Prior splenectomy, splenic irradiation, or splenic artery embolization within 6 months of C1D1
  • GI disease meeting any of the following criteria:

    • Impairment of GI function that could significantly alter the absorption of revumenib (eg. Gastric bypass, gastroparesis)
    • Cirrhosis with a score of B or C, or National Cancer Institute (NCI) Organ Dysfunction Working Group category of Severe Dysfunction
    • Inability to swallow oral medications
  • Any of the following cardiac abnormalities:

    • Any of the following within the 6 months before study entry: myocardial infarction, uncontrolled/unstable angina, congestive heart failure ( Class ≥II), life-threatening, uncontrolled arrhythmia, cerebrovascular accident or . Participants with controlled atrial fibrillation are allowed to enroll
    • QTcF (Fridericia's correction) > 450ms at screening
    • Diagnosis of suspicion of Long QT syndrome or family history of Long QT syndrome
  • Recipient of organ transplant
  • Other within the last three years, other than curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, organ-confined or treated non- prostate cancer with normal prostate-specific antigen, in situ breast carcinoma after complete surgical resection, or superficial/non-invasive transitional cell bladder carcinoma.
  • Presence of uncontrolled active infection of any type. Mild to moderate localized infections under control with antibiotic treatment are acceptable for study entry. Patients with ongoing serious infection are not eligible regardless of antimicrobial therapy. Prophylactic antibiotics are acceptable per NCCN infection guidelines.
  • If participant is known to be (HIV)-positive, they must have an undetectable HIV viral load within the previous 6 months. If viral load testing has not been performed within the previous 6 months, it much be performed during screening.
  • Known active or chronic , or active infection. Participants with a history of HCV infection who have completed curative therapy for HCV at least 12 weeks before the Screening Visit and have a documented undetectable viral load at the Screening Visit are eligible for inclusion.
  • The following exclusions apply related to concomitant use of inhibitors and inducers:

    • Participants who will not receive revumenib with coadministration of a strong CYP3A4i (eg, itraconazole, ketoconazole, posaconazole, or voriconazole) must discontinue all strong CYP3A4 inhibitors at least 7 days or 5 half-lives, whichever is longer, before the first dose of revumenib. They will receive goal dose of revumenib 270 mg Q12h and they may continue to receive moderate or weak CYP3A4 inhibitors, including fluconazole and isavuconazole.
    • Participants who will receive revumenib with coadministration of a strong CYP3A4i (eg, itraconazole, ketoconazole, posaconazole, or voriconazole) must have started the treatment at least 24 hours before the first dose of revumenib. They will receive goal dose of revumenib 160 mg Q12h.
    • Concomitant use of a strong or moderate CYP3A4 inducer is prohibited while on study. Strong or moderate inducers of CYP3A4 should be discontinued at least five half-lives or 14 days (whichever is longer) prior to the first dose of revumenib.
  • Participants requiring the concurrent use of medications known or suspected to prolong the QT/QTc interval, with the exception of drugs with low risk of QT/QTc prolongation that are used as standard supportive therapies (eg, diphenhydramine, famotidine, ondansetron, sulfamethoxazole and trimethoprim) and the azoles permitted. Females who are pregnant or lactating.
  • Any serious, unstable medical or psychiatric condition that would prevent (as judged by the Investigator) the participant from signing the informed consent form or any condition, including the presence of laboratory abnormalities and inability to swallow pills, which places the participant at unacceptable risk if they were to participate in the study or confounds the ability to interpret data from the study.
  • Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or sponsor staff directly involved with this trial, unless prospective IRB approval (by chair or designee) is given allowing exception to this criterion for a specific participant.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    COHORT-1 (revumenib monotherapy)

    Revumenib monotherapy utilizing a 3+3 dose-escalation design

    Drug: Revumenib

  • Experimental
    COHORT-2 (revumenib added to JAK inhibitor therapy)

    Dosage of revumenib from Cohort 1 plus JAK inhibitor therapy (ruxolitinib, fedratinib, or momelotinib)

    Drug: Revumenib · Drug: Ruxolitinib · Drug: FEDRATINIB · Drug: Momelotinib

Interventions

  • Dose Level 1: Revumenib 160mg twice daily or 110mg twice daily Dose Level 2: Revumenib 270mg twice daily or 160mg twice daily

    Also known as: Revuforj)

  • Part of routine care. Participants to continue on dosage as prescribed by provider, 5 to 20 mg BID

  • Part of routine care. Participants to continue on dosage as prescribed by provider, 100 mg to 400 mg daily.

  • Part of routine care. Participants to continue on dosage as prescribed by provider, 100 mg to 200 mg daily.

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity (DLT)

    (COHORT-1) Dose limiting toxicity (DLT) defined as according to the NCI CTCAE v6. AEs attributable to the study agents (possibly / probably / definitely related) will count towards the toxicity stopping boundaries. These include, but not limited to, neutrophil count decreased, thrombocytopenia, and other non-hematologic AEs

    Time frame: 2 months

  2. Number of Treatment related adverse events (AEs)

    (COHORT-1) Number of treatment specific adverse events (AEs) by CTCAE v6.0 (COHORT-2) during dose escalation phase

    Time frame: 6 months

  3. Overall response rate (ORR) for COHORT-2

    (COHORT-2) Overall response rate (ORR) defined as CR, PR, or CI by the revised IWG-MRT and ELN criteria after 6 cycles of therapy (each cycle is one month.)

    Time frame: 6 months

Secondary outcomes

  1. Overall response rate (ORR) for COHORT 1

    (COHORT-1) Overall response rate (ORR) defined as a CR, PR, or CI by the revised IWG-MRT and ELN criteria after 6 cycles of treatment

    Time frame: 6 months

  2. Number of treatment related grade ≥ 3 AEs

    (COHORT-2) AEs and serious adverse events (SAEs), as measured by CTCAE v6.0: Number of grade ≥ 3 AEs using CTCAE v6.0.

    Time frame: 6 months

  3. Proportion of participants achieving CI

    Proportion of participants achieving CI at cycle 3 and cycle 6 by IWG-MRT and ELN criteria: * Anemia response: per IWG-MRT and ELN criteria with screening hemoglobin \< 10 g/dL or transfusion dependency * Spleen response: per IWG-MRT and ELN criteria with baseline spleen volume \> 450 cm3 * Symptom benefit: per IWG-MRT and ELN criteria with baseline MFSAF v4.0 TSS ≥ 10

    Time frame: 3 months and 6 months

  4. Change in spleen volume

    Spleen volume reduction of ≥35% or ≥25% compared to baseline in patients with baseline spleen volume \>450cm\^3 at completion of cycle 3 and cycle 6

    Time frame: 3 months and 6 months

  5. Participants achieving anemia response

    Anemia response as defined by proposed 2024 IWG-ELN criteria in transfusion-dependent or non-transfusion-dependent patients

    Time frame: 6 months

  6. Change in symptom response

    Symptom response as defined by 50% reduction from baseline in MPN-SAF TSS at completion of 3 and 6 cycles and by median change in symptom score.

    Time frame: 3 months and 6 months

07

Study locations

1 site
  • Icahn School of Medicine at the Mount Sinai Hospital
    New York, New York 10029, United States
08

References and documents

Individual participant data

Plan to share: No — The completed dataset is the sole property of the Sponsor-Investigator's institution and should not be exported to third parties, except for authorized representatives of appropriate Health/Regulatory Authorities, without permission from the Sponsor-investigator and their institution.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

Of 27 phase 1/2 interventional studies under Primary Myelofibrosis, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 125. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2026
First posted
Jul 29, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 1, 2028
CompletionEst.
Dec 1, 2028
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07734077
Lead sponsor
John Mascarenhas
Responsible party
John Mascarenhas (Professor, Icahn School of Medicine at Mount Sinai) — Sponsor-investigator
First posted
Jul 29, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Jul 29, 2026

Study contacts

Gillian Sanchez
Contact
gillian.sanchez@mssm.edu
(212) 241-1391
Shakira Forde
Contact
shakira.forde@mssm.edu
John Mascarenhas, MD
study chair · Icahn School of Medicine at Mount Sinai
Anthony M Hunter, MD
study chair · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Revumenib

Start the discussion